Ontology highlight
ABSTRACT:
SUBMITTER: Frias J
PROVIDER: S-EPMC6099242 | biostudies-literature | 2018 Sep
REPOSITORIES: biostudies-literature
Frias Juan J Puig Domingo Manuel M Meneghini Luigi L Napoli Raffaele R Liu Minzhi M Soltes Rak Erika E Aroda Vanita R VR
Diabetes, obesity & metabolism 20180613 9
The present post hoc analysis of two 30-week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan-O trial) or basal insulin (LixiLan-L trial). Time to control, defined as days to achieve glycated haemoglobin (HbA1c) <53 mmol/mol (<7%) or fasting plasma glucose (FPG) ≤7.2 mmol/L, was estimated usi ...[more]